Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.
Cogstate Ltd announced it will host its Financial Year 2025 Results webinar and a separate webinar on Alzheimer’s breakthroughs, highlighting its role in supporting clinical trials and commercialization in Alzheimer’s disease therapeutics. These events underscore Cogstate’s strategic positioning in the neuroscience technology industry, particularly in advancing Alzheimer’s disease drug development, which could have significant implications for stakeholders involved in biopharmaceutical research and healthcare.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company that focuses on optimizing brain health assessments to aid in the development of new medicines and provide earlier clinical insights in healthcare. The company offers computerized cognitive tests and electronic clinical outcome assessment solutions, supporting clinical trials and commercialization, particularly in the biopharmaceutical industry. Cogstate has partnered with Eisai to distribute its assessments in the USA and Asia, aiming to provide accurate digital measures of cognition for primary care physicians and consumers.
YTD Price Performance: 74.16%
Average Trading Volume: 99,076
Technical Sentiment Signal: Buy
Current Market Cap: A$309M
Find detailed analytics on CGS stock on TipRanks’ Stock Analysis page.